 NEW YORK, Oct. 18, 2021 GLOBE NEWSWIRE -- Lucid Diagnostics Inc. Nasdaq: LUCD Lucid a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Nasdaq: PAVM, PAVMZ PAVmed, today announced the closing on October 18, 2021 of its initial public offering the Offering of 5,000,000 shares of common stock at a price to the public of 14.00 per share for total gross proceeds of 70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses. 